CYCLOTRONS AND POSITRON EMISSION TOMOGRAPHY RADIOPHARMACEUTICALS FOR CLINICAL IMAGING

被引:26
|
作者
SAHA, GB
MACINTYRE, WJ
GO, RT
机构
[1] Department of Nuclear Medicine, Cleveland Clinic Foundation, Cleveland, OH
关键词
D O I
10.1016/S0001-2998(05)80143-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Positron emission tomography (PET) requires positronemitting radionuclides that emit 511-keV photons detectable by PET imagers. Positron-emitting radionuclides are commonly produced in charged particle accelerators, eg, linear accelerators or cyclotrons. The most widely available radiopharmaceuticals for PET imaging are carbon-11-, nitrogen-13-, and oxygen-15-labeled compounds, many of which, either in their normal state or incorporated in other compounds, serve as physiological tracers. Other useful PET radiopharmaceuticals include fluorine-18-, bromine-75-, gallium-68 (68Ga)-, rubidium-82 (82Rb)-, and copper-62 (62Cu)-labeled compounds. Many positron emitters have short half-lives and thus require on-site cyclotrons for application, and others (68Ga, 82Rb, and 62Cu) are available from radionuclide generators using relatively long-lived parent radionuclides. This review is divided into two sections: cyclotrons and PET radiopharmaceuticals for clinical imaging. In the cyclotron section, the principle of operation of the cyclotron, types of cyclotrons, medical cyclotrons, and production of radionuclides are discussed. In the section on PET radiopharmaceuticals, the synthesis and clinical use of PET radiopharmaceuticals are described. © 1991 W.B. Saunders Company. All rights reserved.
引用
收藏
页码:150 / 161
页数:12
相关论文
共 50 条
  • [21] Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals
    Cai, Zhengxin
    Anderson, Carolyn J.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2014, 57 (04): : 224 - 230
  • [23] Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals and Positron Emission Tomography (PET)
    Shokeen, Monica
    Anderson, Carolyn J.
    ACCOUNTS OF CHEMICAL RESEARCH, 2009, 42 (07) : 832 - 841
  • [24] Methylation as a method for synthesis of radiopharmaceuticals for positron emission tomography
    Gomzina, N. A.
    Kuznetsova, O. F.
    Vaulina, D. D.
    RUSSIAN CHEMICAL BULLETIN, 2015, 64 (07) : 1536 - 1546
  • [25] Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer
    Sakulpisuti, Chaninart
    Charoenphun, Putthiporn
    Chamroonrat, Wichana
    MOLECULES, 2022, 27 (15):
  • [26] Methylation as a method for synthesis of radiopharmaceuticals for positron emission tomography
    Gomzina N.A.
    Kuznetsova O.F.
    Vaulina D.D.
    Russian Chemical Bulletin, 2015, 64 (7) : 1536 - 1546
  • [27] The Next Generation of Positron Emission Tomography Radiopharmaceuticals in Oncology
    Rice, Samuel L.
    Roney, Celeste A.
    Daumar, Pierre
    Lewis, Jason S.
    SEMINARS IN NUCLEAR MEDICINE, 2011, 41 (04) : 265 - 282
  • [28] POSITRON EMISSION TOMOGRAPHY WITH O-15 RADIOPHARMACEUTICALS
    RAICHLE, ME
    ARCHIVES OF NEUROLOGY, 1983, 40 (12) : 765 - 766
  • [29] Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review
    Theodoropoulos, Athanasios S.
    Gkiozos, Ioannis
    Kontopyrgias, Georgios
    Charpidou, Adrianni
    Kotteas, Elias
    Kyrgias, George
    Tolia, Maria
    SAGE OPEN MEDICINE, 2020, 8
  • [30] Clinical positron emission tomography imaging - Current applications
    Goh, ASW
    Ng, DCE
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2003, 32 (04) : 507 - 517